CStone Pharmaceuticals
CSPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $25 | $153 | $254 | $202 |
| % Growth | -83.8% | -39.8% | 25.6% | – |
| Cost of Goods Sold | $71 | $85 | $82 | $52 |
| Gross Profit | -$46 | $68 | $172 | $151 |
| % Margin | -187.6% | 44.5% | 67.7% | 74.5% |
| R&D Expenses | $53 | $68 | $66 | $341 |
| G&A Expenses | $22 | $29 | $45 | $92 |
| SG&A Expenses | $40 | $102 | $109 | $161 |
| Sales & Mktg Exp. | $18 | $71 | $63 | $68 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $92 | $171 | $176 | $407 |
| Operating Income | -$139 | -$102 | -$4 | -$352 |
| % Margin | -560.5% | -66.9% | -1.4% | -173.7% |
| Other Income/Exp. Net | $3 | -$4 | $19 | $194 |
| Pre-Tax Income | -$135 | -$107 | $16 | -$158 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$135 | -$107 | $16 | -$158 |
| % Margin | -546.4% | -69.9% | 6.2% | -78.1% |
| EPS | -0.1 | -0.084 | 0.01 | -0.124 |
| % Growth | -19.3% | -938% | 108.1% | – |
| EPS Diluted | -0.1 | -0.084 | 0.012 | -0.124 |
| Weighted Avg Shares Out | 1,287 | 1,277 | 1,570 | 1,274 |
| Weighted Avg Shares Out Dil | 1,314 | 1,277 | 1,276 | 1,274 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $15 |
| Interest Expense | $3 | $2 | $0 | $0 |
| Depreciation & Amortization | $3 | $6 | $7 | $9 |
| EBITDA | -$133 | -$85 | $3 | -$342 |
| % Margin | -538.3% | -55.7% | 1.3% | -169.2% |